Natera, Inc. $NTRA Shares Purchased by Guided Capital Wealth Management LLC

Guided Capital Wealth Management LLC lifted its holdings in Natera, Inc. (NASDAQ:NTRA) by 24.3% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 15,786 shares of the medical research company’s stock after purchasing an additional 3,085 shares during the period. Natera comprises about 2.5% of Guided Capital Wealth Management LLC’s portfolio, making the stock its 13th largest holding. Guided Capital Wealth Management LLC’s holdings in Natera were worth $3,616,000 at the end of the most recent quarter.

Other large investors also recently bought and sold shares of the company. JPMorgan Chase & Co. grew its holdings in shares of Natera by 9.4% during the third quarter. JPMorgan Chase & Co. now owns 11,628,914 shares of the medical research company’s stock worth $1,871,914,000 after buying an additional 1,003,129 shares in the last quarter. Franklin Resources Inc. lifted its stake in shares of Natera by 37.5% in the third quarter. Franklin Resources Inc. now owns 2,665,013 shares of the medical research company’s stock worth $428,987,000 after buying an additional 727,366 shares in the last quarter. AQR Capital Management LLC boosted its position in Natera by 39.0% during the third quarter. AQR Capital Management LLC now owns 2,400,065 shares of the medical research company’s stock worth $386,338,000 after acquiring an additional 673,315 shares during the last quarter. Millennium Management LLC boosted its position in Natera by 215.7% during the third quarter. Millennium Management LLC now owns 527,942 shares of the medical research company’s stock worth $84,983,000 after acquiring an additional 360,733 shares during the last quarter. Finally, Holocene Advisors LP grew its stake in Natera by 118.3% during the 2nd quarter. Holocene Advisors LP now owns 572,832 shares of the medical research company’s stock valued at $96,774,000 after acquiring an additional 310,452 shares in the last quarter. Institutional investors and hedge funds own 99.90% of the company’s stock.

Natera Price Performance

Shares of NTRA stock opened at $199.99 on Wednesday. The firm’s 50-day moving average is $209.42 and its two-hundred day moving average is $208.96. Natera, Inc. has a 12 month low of $125.38 and a 12 month high of $256.36. The company has a market capitalization of $28.34 billion, a PE ratio of -130.71 and a beta of 1.65.

Natera (NASDAQ:NTRA) last posted its earnings results on Thursday, February 26th. The medical research company reported $0.35 earnings per share for the quarter, beating the consensus estimate of ($0.46) by $0.81. The company had revenue of $665.50 million for the quarter, compared to analyst estimates of $600.68 million. Natera had a negative net margin of 9.03% and a negative return on equity of 15.28%. During the same period in the previous year, the business posted ($0.41) EPS. Sell-side analysts forecast that Natera, Inc. will post -1.49 EPS for the current year.

Analysts Set New Price Targets

A number of research firms have commented on NTRA. Zacks Research upgraded shares of Natera from a “strong sell” rating to a “hold” rating in a report on Thursday, January 1st. Barclays boosted their target price on Natera from $230.00 to $270.00 and gave the stock an “overweight” rating in a report on Monday, December 15th. Robert W. Baird increased their price target on Natera from $239.00 to $257.00 and gave the company an “outperform” rating in a report on Friday, February 27th. TD Cowen reiterated a “buy” rating on shares of Natera in a research report on Wednesday, January 7th. Finally, BTIG Research boosted their price objective on Natera from $230.00 to $260.00 and gave the stock a “buy” rating in a research note on Friday, December 5th. One analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $253.47.

Insiders Place Their Bets

In related news, CEO Steven Leonard Chapman sold 85,299 shares of the stock in a transaction that occurred on Monday, February 2nd. The stock was sold at an average price of $230.72, for a total value of $19,680,185.28. Following the completion of the transaction, the chief executive officer directly owned 127,881 shares in the company, valued at approximately $29,504,704.32. This represents a 40.01% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider John Fesko sold 17,806 shares of the firm’s stock in a transaction on Tuesday, January 20th. The stock was sold at an average price of $234.74, for a total value of $4,179,780.44. Following the sale, the insider directly owned 177,591 shares of the company’s stock, valued at approximately $41,687,711.34. This trade represents a 9.11% decrease in their position. The SEC filing for this sale provides additional information. Over the last three months, insiders have sold 318,344 shares of company stock valued at $74,091,416. Insiders own 5.63% of the company’s stock.

About Natera

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.